Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan

[1]  A. Glasmacher,et al.  Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial , 2012, Haematologica.

[2]  J. Snowden,et al.  Guidelines for supportive care in multiple myeloma 2011 , 2011, British journal of haematology.

[3]  M. Boccadoro,et al.  Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. H. Lee,et al.  Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide , 2010, Annals of Hematology.

[5]  Robert A Kyle,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. , 2009, Mayo Clinic proceedings.

[6]  P. Sonneveld,et al.  High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. , 2009, Blood.

[7]  A. Falanga,et al.  Venous thromboembolism in the hematologic malignancies , 2012, Current opinion in oncology.

[8]  B. Pégourié,et al.  Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Boccadoro,et al.  Thalidomide for treatment of multiple myeloma: 10 years later. , 2008, Blood.

[10]  B. Barlogie,et al.  Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma , 2008, Leukemia.

[11]  B. Pégourié,et al.  Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial , 2007, The Lancet.

[12]  A. Cheng,et al.  Epidemiology of multiple myeloma in Taiwan , 2007, Cancer.

[13]  Chien-Yi Chen,et al.  Seroprevalence of Helicobacter pylori Infection Among Schoolchildren and Teachers in Taiwan , 2007, Helicobacter.

[14]  H. Sawada,et al.  Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[15]  T. Chao,et al.  Randomized Phase II Trial of Thalidomide Alone versus Thalidomide Plus Interferon Alpha in Patients with Refractory Multiple Myeloma , 2007, Cancer investigation.

[16]  Vincenzo Callea,et al.  Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial , 2006, The Lancet.

[17]  M. Dimopoulos,et al.  Treatment of plasma cell dyscrasias with thalidomide and its derivatives. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Ko,et al.  Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma , 2003, Annals of Hematology.

[19]  A. Anagnostopoulos,et al.  Thalidomide and dexamethasone for resistant multiple myeloma , 2003, British journal of haematology.

[20]  D. Graham,et al.  Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. , 2002, Archives of internal medicine.

[21]  B. Barlogie,et al.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.

[22]  M. Dimopoulos,et al.  Thalidomide and dexamethasone combination for refractory multiple myeloma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  F. Chan,et al.  Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. , 2001, The New England journal of medicine.

[24]  J. Heit,et al.  Prevention of venous thromboembolism. , 2001, Clinics in geriatric medicine.

[25]  K. Beullens,et al.  Results From a Prospective Cohort Study , 2013 .

[26]  C. Keenan,et al.  Effects of race and ethnicity on the incidence of venous thromboembolism. , 2009, Thrombosis research.

[27]  Wei Chen,et al.  International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation , 2009, Leukemia.

[28]  C. Colwell,et al.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[29]  R. Bataille,et al.  Prognostic factors and staging in multiple myeloma: a reappraisal. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.